LifeSci Advisors, LLC’s Post

WEBINAR ALERT! 👉Join Dr. Tyler F. Stewart, a genitourinary malignancies expert from UC San Diego, as he walks you through the journey of treating muscle invasive and advanced bladder cancer. From traditional chemotherapy to today's immunotherapy, discover the progress since BCAN began in 2005. Learn about personalized therapies, Antibody Drug Conjugates, and groundbreaking first-line combinations reshaping bladder cancer care. Understand the evolving landscape of bladder preservation. Click here to register: https://lnkd.in/gKtHvC3e

🧐Check out the #Article "Exploring Connections between Oral Microbiota, Short-Chain Fatty Acids, and Specific Cancer Types: A Study of Oral Cancer, Head and Neck Cancer, Pancreatic Cancer, and Gastric Cancer" 👏by Zahra Nouri et al. Access the full paper here👉 https://lnkd.in/dk2xpG6g Keywords: oral microbiota; machine learning; SCFAs;

WEBINAR ALERT! 👉Join Dr. Tyler F. Stewart, a genitourinary malignancies expert from UC San Diego on June 11th, as he walks you through the journey of treating muscle invasive and advanced bladder cancer. From traditional chemotherapy to today's immunotherapy, discover the progress since BCAN began in 2005. Learn about personalized therapies, Antibody Drug Conjugates, and groundbreaking first-line combinations reshaping bladder cancer care. Understand the evolving landscape of bladder preservation. Click here to register: https://lnkd.in/gKtHvC3e

Today is #WorldCancerResearchDay, highlighting the critical importance of advancing studies and trials aimed at understanding the disease and developing effective treatments. Today of all days, we are sharing our latest case study, conducted in partnership with a top-10 pharma company on non-small cell lung cancer (NSCLC). The study focuses on metastatic non-small cell lung cancer (NSCLC) in patients with wild-type (WT) tumor profiles, examining diagnosis-to-treatment timelines and the correlation between smoking and disease development. Learn how this research contributes to better data-driven decisions and improved patient outcomes: https://lnkd.in/dmHtpnWt

In our newest Pharmacy Times Insights Series, titled "Advancing Treatment of EGFR-Positive Metastatic Non-Small Cell Lung Cancer", Cara Chang explores the prevalence of EGFR mutations in NSCLC and takes a dive into the different therapeutic options for patients. Navigate to the link below to watch the full episode on pharmacytimes.com: https://lnkd.in/dGdsVhMu

🎉 Excited to Announce Our Latest Publication! Our team has just published a manuscript evaluating the real-world effectiveness of PARP inhibitor therapy in advanced ovarian cancer by biomarker-selected patient groups, using rigorous statistical methods and practices. We found more favorable outcomes for maintenance PARPi compared to no maintenance PARPi use for those with HRD signature(+) tumors independent of BRCA status, including patients testing BRCA(-). In the HRDsig(-) group, we observed no discernible enrichment for more favorable outcomes. We look forward to engaging with the research community on how these findings might refine clinical practices moving forward! Ryon Graf, PhD, Julia Elvin, Natalie Danziger, Gerald Li, Ethan Sokol, Alexa Schrock, PhD, Ericka Ebot, Neeru Bhardwaj, Tanesha Norris

#sponsored Do you have hormone receptor-positive, early-stage breast cancer and wonder what your risk of recurrence is? Genomic tests can help provide personalized information to assess your risk, and how length of treatment may or may not reduce that risk. The Breast Cancer Index® test provides an estimate of your individual risk of distant recurrence between years 5 and 10, and whether longer anti-estrogen therapy is likely to help. Knowing your personalized risk and what you can do about it can help reduce anxiety as a breast cancer survivor. #breastcancerindex #findyourfinish @Hologic @breastcancerorg #breastcancersurvivor

In the realm of metastatic colorectal cancer treatment, understanding treatment options for refractory cases is crucial. Dat Le, PharmD, BCOP, from The James Cancer Hospital at The Ohio State University, shares insights from his session, To Infinity and Beyond 5FU: Updates in the Treatment of Metastatic Colorectal Cancer, at our recent Spring Forum. Learn essential counseling points for medications used in refractory cases and gain a deeper understanding of this vital aspect of patient care through the presentation that is available on NCODA CONNECT: https://bit.ly/4aNwpSQ

Indaptus Therapeutics’ CEO, Jeffrey Meckler, and CMO, Roger Waltzman, sat down to discuss a few key takeaways from our recent presentation at #ASCO2024. In this video, we cover: Decoy20 Strategy: Discover how our novel approach stimulates both the innate and adaptive immune systems, with a remarkable tolerability profile thanks to a significant reduction in LPS. Conference Highlights: Learn about the promising developments in CAR therapies for solid tumors and how #Decoy20 could potentially enhance these treatments. Reinforcement of Our Approach: Hear about other studies, such as Eikon Therapeutics’ EIK1001 + Pembro, that support our broad immune activation strategy. Please join us as we continue to lead the way in developing innovative new cancer treatments. #IndaptusTherapeutics #CancerResearch #Immunotherapy

In a trailblazing move to improve cancer care, a panel discussion titled ‘Cancer Moonshots Across the Continuum’ was recently held, moderated by #JPMorgan. The panel focused on strategies to cut the cost of cancer care and the mortality rate in half. This article delves into the key takeaways from this impactful discussion and the consequent implications for the future of cancer care.